Meridian Bioscience Inc. (NASDAQ:vivo) announced a quarterly dividend on Thursday, November 10th. Shareholders of record on Monday, November 21st will be given a dividend of 0.20 per share on Thursday, December 1st. This represents a $0.80 dividend on an annualized basis and a yield of 4.69%. The ex-dividend date is Thursday, November 17th.

Shares of Meridian Bioscience (NASDAQ:VIVO) opened at 17.05 on Friday. The stock has a market cap of $717.57 million, a P/E ratio of 20.30 and a beta of 0.94. Meridian Bioscience has a 52-week low of $15.75 and a 52-week high of $21.49. The firm’s 50-day moving average price is $17.98 and its 200-day moving average price is $19.06.

Meridian Bioscience (NASDAQ:VIVO) last announced its earnings results on Thursday, November 10th. The company reported $0.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.14. The business earned $47 million during the quarter, compared to analyst estimates of $47.17 million. Meridian Bioscience had a net margin of 17.95% and a return on equity of 21.51%. The company’s quarterly revenue was down .2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.20 EPS. Equities analysts predict that Meridian Bioscience will post $0.80 EPS for the current year.

Dividend History for Meridian Bioscience (NASDAQ:vivo)

A number of brokerages have recently issued reports on VIVO. Canaccord Genuity reissued a “hold” rating and set a $20.00 price objective on shares of Meridian Bioscience in a research report on Monday, August 1st. Hilliard Lyons downgraded shares of Meridian Bioscience from a “buy” rating to a “hold” rating in a research report on Friday, July 29th. Finally, Zacks Investment Research raised shares of Meridian Bioscience from a “sell” rating to a “hold” rating in a research report on Tuesday, October 11th. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $20.00.

In other news, Chairman John A. Kraeutler bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 4th. The stock was bought at an average price of $16.13 per share, with a total value of $80,650.00. Following the acquisition, the chairman now owns 316,683 shares of the company’s stock, valued at approximately $5,108,096.79. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Lawrence Baldini bought 4,900 shares of the company’s stock in a transaction that occurred on Thursday, November 3rd. The stock was purchased at an average cost of $16.00 per share, with a total value of $78,400.00. Following the acquisition, the executive vice president now directly owns 95,501 shares in the company, valued at approximately $1,528,016. The disclosure for this purchase can be found here. Insiders own 2.00% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. KCG Holdings Inc. increased its position in shares of Meridian Bioscience by 3.5% in the third quarter. KCG Holdings Inc. now owns 12,313 shares of the company’s stock valued at $238,000 after buying an additional 420 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Meridian Bioscience by 3.6% in the third quarter. Principal Financial Group Inc. now owns 319,660 shares of the company’s stock valued at $6,167,000 after buying an additional 11,218 shares in the last quarter. Northern Trust Corp increased its position in shares of Meridian Bioscience by 1.0% in the third quarter. Northern Trust Corp now owns 515,384 shares of the company’s stock valued at $9,941,000 after buying an additional 5,247 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Meridian Bioscience by 0.9% in the third quarter. California State Teachers Retirement System now owns 88,249 shares of the company’s stock valued at $1,702,000 after buying an additional 800 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of Meridian Bioscience by 4.1% in the third quarter. Ameriprise Financial Inc. now owns 218,967 shares of the company’s stock valued at $4,223,000 after buying an additional 8,687 shares in the last quarter. 86.99% of the stock is owned by institutional investors.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc (Meridian) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

5 Day Chart for NASDAQ:VIVO

Receive News & Stock Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related stocks with our FREE daily email newsletter.